FDA in­di­cates will­ing­ness to ap­prove Bio­gen ALS drug de­spite failed PhI­II study

Ahead of Wednes­day’s ad­vi­so­ry com­mit­tee hear­ing to dis­cuss Bio­gen’s ALS drug tofersen, the FDA ap­peared open to ap­prov­ing the drug, new­ly re­leased brief­ing doc­u­ments show …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.